<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Molecular biology of prostate cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Molecular biology of prostate cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Molecular biology of prostate cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Vander Griend, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">W Robert Lee, MD, MS, MEd</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prostate cancer is the second most common cancer in men worldwide according to data from the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fgco.iarc.fr%2Ftoday%2Fdata%2Ffactsheets%2Fpopulations%2F900-world-fact-sheets.pdf&amp;token=7AdXJKJ8tZtCySAVh4KdG1ANuFP%2B%2FgZCYzj9ip594WCRqQxV1DlnVzyEG6P5S6c%2FchWpxRmhHixRVKBdgifj1giN4SsqnT7UwfMaoUv0vQE%3D&amp;TOPIC_ID=6926" target="_blank">GLOBOCAN</a> database. If completely localized within the capsule of the gland, some favorable-risk prostate cancers can be managed with active surveillance or potentially cured by definitive local therapy (eg, radical prostatectomy, radiation therapy, brachytherapy). In contrast, non-organ-confined disease is often fatal. (See  <a class="medical medical_review" href="/d/html/6940.html" rel="external">"Initial approach to low- and very low-risk clinically localized prostate cancer"</a> and  <a class="medical medical_review" href="/d/html/6941.html" rel="external">"Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer"</a>.) </p><p>Here we will provide an overview of the molecular changes that are proposed to be involved in the initiation and progression of prostate cancer, particularly those that accompany metastatic disease and castration resistance. The diagnosis, staging, and treatment of prostate cancer are covered elsewhere. (See appropriate topic reviews.)</p><p class="headingAnchor" id="H3573674667"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Metastatic prostate cancers can be lethal because they heterogeneously contain both androgen-dependent and androgen-independent malignant cells. For those cells that are androgen dependent, a critical level of androgen is required to activate a sufficient number of androgen receptors (ARs) so that transcription of death-signaling genes is repressed [<a href="#rid1">1</a>]. Androgen ablation therapies allow these genes to be expressed, triggering the biochemical cascade that results in apoptotic cell death, resulting in the eradication of the large fraction of androgen-dependent cancer cells [<a href="#rid2">2,3</a>]. In contrast, androgen ablation does not induce apoptosis in androgen-independent cells [<a href="#rid4">4</a>]; their eventual outgrowth is responsible for the lethality of advanced disease. (See  <a class="medical medical_review" href="/d/html/6941.html" rel="external">"Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer"</a>.)</p><p>Although prostate cancer typically presents in men over the age of 65, a growing body of evidence suggests that prostatic carcinogenesis is initiated much earlier [<a href="#rid5">5</a>]. Prostatic intraepithelial neoplasia (PIN) is thought to represent a precursor of adenocarcinoma, although not all cases progress to invasive disease. One of the most pressing clinical problems presented by prostate cancer is the difficulty in predicting its clinical course based on clinical or histologic features. (See  <a class="medical medical_review" href="/d/html/6925.html" rel="external">"Precancerous lesions of the prostate: Pathology and clinical implications"</a>.)</p><p>Prostate cancer progression has been related to a number of genetic abnormalities that affect the AR and other molecules that are involved in the regulation of cell survival and apoptosis [<a href="#rid6">6</a>]. A multistep process of prostate carcinogenesis has been proposed in which progressive accumulation of genetic alterations is postulated to facilitate cellular transformation from normal prostate epithelium to PIN, invasive neoplasia, and castration resistance [<a href="#rid6">6,7</a>].</p><p>Over the last decade, a number of genes involved in or associated with prostate cancer have been identified and characterized [<a href="#rid6">6</a>]. Many of these genes or their protein products are under study for their value in clinical staging (sometimes termed "molecular staging") with the goal of more closely tailoring the selection of treatment to expected prognosis [<a href="#rid8">8</a>]. Perhaps more importantly, mechanistic studies to determine the biochemical result of specific molecular changes might reveal additional targets for therapy. Unfortunately, the heterogeneity of prostate cancers, the variability in analytic techniques, and the lack of suitable model systems for different stages of prostate progression have hampered progress. (See  <a class="medical medical_review" href="/d/html/6939.html" rel="external">"Clinical presentation and diagnosis of prostate cancer"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CHROMOSOMAL ABERRATIONS AND CANDIDATE GENES</span><span class="headingEndMark"> — </span>Techniques such as fluorescence in situ hybridization (FISH), comparative genomic hybridization, and microsatellite analysis have demonstrated losses or gains in various chromosomes that are associated with prostate cancer progression [<a href="#rid9">9-12</a>]. In many instances, the target gene or genes have been identified. Further advances in positional cloning technology and the information provided by the human genome project are expected to facilitate the identification of candidate genes within these chromosomal regions.</p><p>There are three categories of chromosomal changes that may play a role in the development and progression of prostate cancer: those that are associated with genetic predisposition (eg, 1q deletions), somatic alterations that result in amplification of presumed oncogenes (eg, 7p and 8q), and somatic alterations that result in the loss of function of presumed tumor suppressor genes (eg, 8p, 10q, 12q, 13q, and 17p). Here we will provide an overview of selected molecular changes that occur during prostate cancer development and progression, with a particular emphasis on their prognostic and therapeutic value. Specific details of these chromosomal alterations are beyond the scope of this review and are discussed more in depth elsewhere [<a href="#rid13">13,14</a>]. </p><p>Genetic factors that may influence prostate cancer risk are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6938.html" rel="external">"Risk factors for prostate cancer"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Oncogenes</span><span class="headingEndMark"> — </span>Oncogenes are homologs of normal cellular genes in which a mutational change results in constitutive activation and gain of function. These mutations either accelerate cellular growth and/or proliferation (eg, c-myc, beta catenin, human epidermal growth factor 2 [HER2], Ras), or facilitate abnormal cell division (eg, mitogen-activated protein kinase phosphatase 1 [MKP-1], B cell leukemia/lymphoma [bcl-2], telomerase).</p><p class="headingAnchor" id="H4"><span class="h3">c-myc</span><span class="headingEndMark"> — </span>Gain of chromosome 8q sequences is a common feature of prostate cancer, particularly metastatic tumors [<a href="#rid15">15</a>]. The target gene is not known, but one candidate is c-myc, which is amplified in a subset of advanced tumors. The myc oncogene, located at chromosome 8q24, encodes a nuclear protein that is involved in the control of normal cell growth, differentiation, and apoptosis. Increasing levels of overexpression correlate with advancing stage and grade of prostate cancer [<a href="#rid16">16-18</a>], and high levels of amplification are found in a subset of men with androgen-independent disease [<a href="#rid19">19-21</a>].</p><p class="headingAnchor" id="H5"><span class="h3">MKP-1</span><span class="headingEndMark"> — </span>Several oncogenes involved in prostate carcinogenesis activate mitogen-activated protein (MAP) kinases, which can relay both proliferative (via extracellular regulated kinases [ERK]) and apoptotic signals (via Jun N-terminal protein kinases [JNK]) to the nucleus. MKP-1 is a dual-specificity MAP kinase phosphatase that dephosphorylates both phosphotyrosine and phosphothreonine residues on the JNK and ERK MAP kinases, providing overall protection from apoptotic influences. Overexpression of MKP-1 has been detected in the earliest stages of prostate cancer, including prostatic intraepithelial neoplasia (PIN) [<a href="#rid22">22,23</a>]. In one report of 51 prostate cancers, MKP-1 was overexpressed in PIN lesions, but its expression decreased with higher histologic grade and advanced disease stage [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Bcl-2</span><span class="headingEndMark"> — </span>Overexpression of the bcl-2 oncogene by prostate cancers confers resistance to apoptosis [<a href="#rid24">24</a>], and upregulation of bcl-2 (particularly in conjunction with p53 mutations, see below) is a frequent and important step in the progression to advanced or castration-resistant disease [<a href="#rid25">25-29</a>]. Bcl-2 tends to be expressed more strongly as malignant change progresses along the continuum from preinvasive to metastatic cancer [<a href="#rid30">30-32</a>]. As a result, the bcl-2 protein is a potential target for clinical intervention, particularly using antisense molecules such as oblimersen [<a href="#rid33">33-35</a>]. Its value as a prognostic marker is less certain [<a href="#rid36">36-39</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Telomerase</span><span class="headingEndMark"> — </span>Telomeres are specialized nucleoprotein structures that cap the ends of linear eukaryotic chromosomes [<a href="#rid40">40</a>]. Because of incomplete DNA replication at the ends of chromosomes, telomeres progressively shorten with each cell division in eukaryotic cells. This progressive loss of telomeres is postulated to be the "clock" by which normal cells senesce with age, and telomere maintenance appears to be an important regulator of cellular life span.</p><p>Telomerase, a ribonucleoprotein enzyme, compensates for telomere shortening during cell division by synthesizing telomeric DNA, thereby maintaining telomere length. In normal somatic cells, telomerase activity is usually undetectable, with the exception of hematopoietic cells, hair follicles, intestinal crypt cells, and epidermal basal cells. In contrast, upregulation of telomerase and amplification of telomeric DNA are detected in many cancers, including up to 90 percent of prostate cancers, and in high-grade PIN [<a href="#rid41">41-47</a>]. Higher-grade cancers appear to have maximally elevated telomerase activity [<a href="#rid46">46,47</a>].</p><p>Telomerase has been exploited both as a diagnostic tool and a therapeutic strategy in prostate cancer. A urinary assay for telomerase has been proposed as a noninvasive means of detecting prostate cancer, while the therapeutic potential of agents targeting telomerase and telomere-associated enzymes is beginning to be explored [<a href="#rid48">48</a>]. </p><p class="headingAnchor" id="H8"><span class="h3">Beta catenin</span><span class="headingEndMark"> — </span>The catenin family of proteins is thought to play a critical role in cell-cell adhesion. However, the role of beta catenin in prostate tumorigenesis appears to be distinct from cell adhesion. Although most cases of prostate cancer show downregulation of beta catenin at the messenger RNA (mRNA) and protein level [<a href="#rid49">49,50</a>], approximately 5 percent contain activating mutations within the beta catenin gene [<a href="#rid51">51,52</a>]. This gain of function mutation results in protein stabilization and accumulation in the nucleus, where beta catenin forms a transcriptional complex that is capable of upregulating target genes, such as the androgen receptor (AR) [<a href="#rid51">51,53</a>]. Up to 20 percent of lethal prostate cancers contain nuclear beta catenin, suggesting a more common role in advanced disease [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Ras pathway</span><span class="headingEndMark"> — </span>The Ras oncogene is thought to be important in pathogenesis in many human malignancies (eg, non-small cell lung cancer).</p><p>In prostate cancer, Ras amplification does not seem to play a major role in disease initiation and development in American men [<a href="#rid55">55,56</a>], although somewhat higher mutation rates are reported in Japanese men [<a href="#rid57">57,58</a>].</p><p>In contrast, epigenetic inactivation of the <em>RASSF1A</em> gene (located on chromosome 3p21) via promoter methylation is present in approximately 60 to 70 percent of prostate cancers, particularly more-aggressive tumors [<a href="#rid59">59-61</a>].</p><p>An alternative mechanism for prostate cancer pathogenesis involves the <em>DAB2IP </em>gene, which encodes a protein that is a negative regulator of the Ras signal transduction pathway. A polymorphism of <em>DAB2IP</em> was associated with aggressive prostate cancer in an exploratory genome-wide association study [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H10"><span class="h3">HER2</span><span class="headingEndMark"> — </span>The protein product of the HER2 oncogene (also known as c-erbB-2) is a receptor tyrosine kinase belonging to the epidermal growth factor receptor (EGFR) family. Its role in prostate tumorigenesis is controversial. HER2 protein overexpression is detected in 20 to 25 percent of hormone-naive primary tumors and in 60 to 78 percent of cancers following androgen ablation [<a href="#rid63">63,64</a>]. However, the biologic significance of this finding is unclear. With the exception of one study [<a href="#rid65">65</a>], high-level amplification of the gene, representing the predominant mechanism of HER2 pathway activation (at least in breast cancer), is not observed in prostate cancer [<a href="#rid19">19,63,64,66,67</a>]. (See  <a class="medical medical_review" href="/d/html/780.html" rel="external">"HER2 and predicting response to therapy in breast cancer"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">EGFR pathway</span><span class="headingEndMark"> — </span>EGFR, also known as HER1 or c-erbB-1, belongs to a family of receptors that includes the HER2 protein (c-erbB-2), as well as HER3 and HER4. EGFR is a transmembrane glycoprotein whose intracellular domain includes a tyrosine kinase, which is a therapeutic target in a number of other malignancies.</p><p>A possible role for EGFR in prostate cancer pathogenesis was suggested by a study of 2497 prostate cancers for whom follow-up data was available [<a href="#rid68">68</a>]. Overall, EGFR was expressed in 18 percent of cases. EGFR expression was associated with higher-grade tumors, more-advanced stage, and a decrease in recurrence-free survival.</p><p class="headingAnchor" id="H12"><span class="h3">Fatty acid synthase</span><span class="headingEndMark"> — </span>A common occurrence in many cancers is the increased synthesis of long-chain fatty acids. Fatty acid synthase (FASN) is a key enzyme in this process. In prostate cancers, FASN expression is thought to function as an oncogene by preventing apoptosis. This is documented by the increased cell proliferation and tumorigenic growth of FASN-expressing prostate cell lines and transgenic models, as well as in human prostate specimens [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H20797464"><span class="h3">HOXB13</span><span class="headingEndMark"> — </span>The homeobox B13 (<em>HOXB13</em>) gene codes for a transcription factor that is important in prostate development. Sequencing studies have identified the G84E variant as associated with hereditary prostate cancer in some families [<a href="#rid70">70</a>]. The mechanism by which <em>HOXB13 </em>acts is not yet understood, but an understanding of this pathway may provide additional insights into sporadic cases of prostate cancer as well. (See  <a class="medical medical_review" href="/d/html/112282.html" rel="external">"Genetic risk factors for prostate cancer"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Oncogenes as a result of a gene fusion event</span><span class="headingEndMark"> — </span>A recurrent gene fusion as a result of a chromosomal rearrangement has been identified in prostate cancer [<a href="#rid71">71</a>]. Fusion of the androgen-regulated gene <em>TMPRSS2</em> and the ETS transcription family members (ERG, ETV1, ETV4, and ETV5) has been described as one of the most common recurrent genomic alterations in prostate cancer [<a href="#rid72">72</a>]. Such TMPRSS2-ERG fusion products are found in nearly one half of prostate-specific antigen (PSA)-screened prostate cancer patients and are absent in biopsies from benign lesions [<a href="#rid73">73-75</a>]. Furthermore, TMPRSS2-ERG fusions show a high correlation with disease recurrence after surgery for localized prostate cancer [<a href="#rid76">76</a>]. Since this initial observation, other permutations of gene fusions have been found, all of which involve an ETS transcription family member fused to a number of partners [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Tumor suppressor genes</span><span class="headingEndMark"> — </span>In contrast to oncogenes, tumor suppressor genes exert their influence by controlling or inhibiting cell growth. When the gene mutates to cause a loss or reduction in function, this removes inhibitory influences on cell growth, thus allowing growth to proceed unchecked. As examples, the wild-type forms of genes such as <em>GSTP1</em> protect cells from DNA damage, and the p53 gene product prevents cells from proliferating after damage has occurred; mutations in these putative tumor suppressor genes result in loss of these functions.</p><p>Deactivation of tumor suppressor genes can result from chromosomal deletion, loss of expression due to promoter hypermethylation, specific genetic mutations that result in deletion of a specific gene, or point mutations that result in the production of an aberrant protein product with reduced function.</p><p class="headingAnchor" id="H15"><span class="h3">PTEN/MMAC1</span><span class="headingEndMark"> — </span>The protein product of the phosphatase and tensin homologue (<em>PTEN</em>, also termed <em>MMAC1</em>) gene, located on chromosome 10q, negatively regulates the phosphoinositide 3-kinase (PI3-kinase)/Akt pathway. This pathway plays a critical role in a variety of growth factor signaling pathways that control the cell cycle and apoptosis. Although germline mutations of <em>MMAC1</em> are found in numerous cancer predisposition syndromes [<a href="#rid77">77</a>], mutations in the <em>PTEN </em>gene have not been found in men with hereditary prostate cancer. (See  <a class="medical medical_review" href="/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes"</a> and  <a class="medical medical_review" href="/d/html/6938.html" rel="external">"Risk factors for prostate cancer"</a>.)</p><p>Nevertheless, <em>PTEN</em> clearly plays an important role in the progression of prostate cancer. <em>PTEN</em> alterations appear to be a late event, possibly influencing metastatic potential and progression to androgen independence rather than tumorigenesis [<a href="#rid78">78,79</a>]. As examples, high rates of loss of heterozygosity (LOH) for 10q are reported in advanced prostate cancer [<a href="#rid80">80,81</a>], and <em>PTEN</em> mutations are more commonly found in metastatic compared with localized prostate cancers (30 to 58 versus 5 to 27 percent of cases, respectively) [<a href="#rid79">79,82-88</a>]. A role for <em>PTEN</em> mutations in resistance to chemotherapy is also proposed [<a href="#rid89">89</a>], and gene therapy approaches using transfected wild-type <em>PTEN </em>are being developed [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Mxi1</span><span class="headingEndMark"> — </span>The product of the <em>Mxi1</em> gene on chromosome 10q is a member of the helix-loop-helix-leucine zipper family and a potential negative regulator of c-myc (see <a class="local">'Oncogenes'</a> above). These proteins seem to be essential in cellular growth control and/or induction and maintenance of the differentiated state [<a href="#rid91">91</a>]. In prostate cancers, loss of <em>Mxi1 </em>expression, rather than point mutation, is the primary means of inactivation [<a href="#rid80">80,92-94</a>]. Mice lacking the Mix1 protein are susceptible to tumorigenesis, and Mxi1-deficient prostate epithelial cells have increased proliferative activity [<a href="#rid91">91</a>]. Others, using subtraction hybridization, have identified <em>Mix-1</em> as one of eight target genes that are differentially expressed in androgen-dependent and androgen-independent prostate cancer xenografts [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H17"><span class="h3">GSTP1</span><span class="headingEndMark"> — </span>Hypermethylation of the p-class glutathione S-transferase (GSTP) gene promoter is possibly the most common genetic event in prostate cancer and appears to be an early event in tumorigenesis [<a href="#rid95">95</a>]. GSTPs are a family of enzymes that participate in detoxification by catalyzing the conjugation of many hydrophobic and electrophilic compounds with reduced glutathione; this protects the cells from environmental carcinogenic factors [<a href="#rid96">96</a>]. Over 90 percent of prostate carcinomas and 70 percent of high-grade PIN lesions have lost <em>GSTP1 </em>expression due to hypermethylation of the 5'-CpG island [<a href="#rid97">97,98</a>].</p><p class="headingAnchor" id="H18"><span class="h3">p53</span><span class="headingEndMark"> — </span>The <em>p53 </em>gene, located at chromosome 17p13.1, encodes a nuclear protein that acts as a transcription factor, blocking the progression of cells through the cell cycle late in the Gap 1 (G1) phase. The<em> p53</em> gene plays a central role in the regulation of transcriptional events in the cell nucleus, particularly in the response to DNA-damaging agents, such as ionizing radiation and a variety of other carcinogens. The ability of wild-type <em>p53 </em>to prevent the proliferation of damaged cells has led to its description as the "guardian of the genome." A mutation in the <em>p53</em> gene abrogates the G1 checkpoint and changes the cellular response to DNA damage, thus promoting genetic instability and the acquisition of additional mutations.</p><p>The significance of <em>p53</em> mutations in prostate cancer is controversial. A number of studies using different analytical tools yield widely varying mutation rates among human prostate cancer specimens, a situation that is complicated by significant intratumoral heterogeneity within a single specimen [<a href="#rid99">99</a>]. Mutations in <em>p53</em> have been reported in 60 to 90 percent of advanced prostate cancers [<a href="#rid100">100</a>], as well as in between 10 to 20 percent of primary tumors [<a href="#rid101">101-105</a>]. The reported incidence in PIN lesions ranges from 6 to 56 percent [<a href="#rid105">105,106</a>].</p><p>Despite these methodologic difficulties, accumulating data support a prognostic role for <em>p53</em> mutations in human prostate cancer. The presence of<em> p53</em> mutations in radical prostatectomy specimens is associated with increased proliferative rates, higher-grade disease, androgen independence, and a poor clinical outcome [<a href="#rid17">17,25,29,36,39,101,102,107-115</a>]. Furthermore, it has been proposed that <em>p53 </em>mutations in primary tumors are associated with increased metastatic potential [<a href="#rid39">39,100,101,116</a>]. In addition, abnormal <em>p53</em> expression has been associated with higher rates of biochemical progression in men managed with radiation therapy and androgen deprivation therapy [<a href="#rid117">117</a>]. In a more recent study, there was a positive correlation between the expression of the proliferation marker Ki-67, p53, and the p53 regulator MDM2 and the development of distant metastases and overall mortality from prostate cancer [<a href="#rid118">118</a>].</p><p>In contrast, studies of p53 assessment in prostate needle biopsies have provided conflicting results, likely due to sampling variability, tumor heterogeneity, and multifocality [<a href="#rid37">37,38,119,120</a>]. A prospective multicenter study is needed to confirm the value of p53 assessment in needle biopsy prior to radical prostatectomy.</p><p>Although human trials have not begun, preclinical results suggest a potential therapeutic benefit for gene therapy using viral constructs that contain wild-type <em>p53</em> in men with prostate cancer [<a href="#rid121">121,122</a>].</p><p class="headingAnchor" id="H19"><span class="h3">TGF-b1</span><span class="headingEndMark"> — </span>In normal prostate epithelial cells, transforming growth factor beta (TGF-b) induces apoptosis and inhibits proliferation. However, prostate tumors frequently do not express TGF-b receptors (type I and II), and as they progress, tumor cells shift to autocrine regulation of TGF-b. TGF-b overexpression coupled with the underexpression of TGF-b receptors allows prostate cancers to escape the growth inhibitory effect of TGF-b.</p><p>In prostate cancers, abnormalities in TGF-b are associated with higher histologic grade, a more malignant phenotype, and greater metastatic potential [<a href="#rid123">123-127</a>]. As an example, in one report of men undergoing prostatectomy for apparently localized disease, elevated preoperative plasma levels of TGF-b were a strong predictor of biochemical progression, presumably the result of occult metastatic disease at the time of surgery [<a href="#rid128">128</a>]. Preoperative levels of TGF-b have been incorporated into a nomogram to predict biochemical progression-free survival following radical prostatectomy, although measurement of preoperative levels is not routine in most centers [<a href="#rid129">129</a>].</p><p class="headingAnchor" id="H20"><span class="h3">Rb/p16 pathway</span><span class="headingEndMark"> — </span>Chromosome 13q is one of the most frequently altered chromosomes in prostate cancer. In one study, 58 percent of primary tumors showed LOH for 13q, and allelic loss was even more frequent in metastatic lesions [<a href="#rid130">130</a>]. Two known tumor suppressor genes (retinoblastoma [<em>Rb</em>] and <em>BRCA2</em>) map to this region, although other putative tumor suppressor genes may also reside in this location [<a href="#rid131">131</a>].</p><p>The <em>Rb </em>gene, so named because deletions or mutations of this gene are critical in the pathogenesis of retinoblastoma, is also involved in the pathogenesis of a variety of other solid tumors. The <em>Rb</em> gene encodes for a nuclear protein (pRb1) that is an important regulator of the cell cycle during the G0/G1 phase; its activity is dependent on its phosphorylation status during the cell cycle. At the end of mitosis and during most of G0/G1, pRb1 is dephosphorylated, which actively suppresses the transition from G1 to synthesis (S) phase. Phosphorylation of pRb1 by cyclin-dependent kinases (CDKs) in late G1 phase leads to its inactivation, thereby leading to cell cycle progression. Multiple CDK inhibitors have been identified (eg, p16INK4A [also called CDKN2A or MTS-1, on chromosome 9p] and p21WAF1/CIP1) that block entry into S phase by decreasing pRb1 phosphorylation. This entire pathway of cell cycle control is often referred to as the Rb/p16 pathway.</p><p>In many solid tumors, dysregulation of the Rb/p16 pathway is an early event in tumorigenesis. However, the role of this pathway in prostate cancer is unclear. In early prostate cancer, deletion of <em>p16</em> and <em>Rb </em>genes is reported in some, but not all, series, and the role of these genetic alterations in tumorigenesis and/or tumor progression remains undefined [<a href="#rid132">132-140</a>]. Other studies suggest that mutations in the <em>Rb </em>gene, and mutation or promoter methylation of the <em>CDKN2A </em>gene are more common in advanced prostate cancer [<a href="#rid134">134,141-147</a>]. Preclinical gene therapy studies using adenoviral vectors containing wild-type <em>p16</em> or<em> Rb</em> genes are underway [<a href="#rid148">148,149</a>].</p><p>Although p21 is a growth inhibitory molecule, most series report expression in 25 to 30 percent of primary prostate tumors [<a href="#rid150">150-153</a>]. Furthermore, overexpression appears to be associated with progression toward androgen-independent disease [<a href="#rid150">150</a>]. In vitro studies of antisense strategies directed against p21 show early promise [<a href="#rid154">154</a>].</p><p class="headingAnchor" id="H21"><span class="h3">CDKI1B</span><span class="headingEndMark"> — </span>The CDK inhibitor 1B gene (<em>CDKI1B</em>, previously called p27/Kip1) maps to 12p12-13.1, a region that is frequently deleted in advanced prostate cancer [<a href="#rid155">155</a>]. <em>CDKI1B</em> is an inhibitor of CDK4; as such, it is a negative regulator of cell cycle initiation. In regards to prostate cancer, several clinical studies have indicated a loss of CDKI1B protein expression in prostate cancers and PIN, indicating this as a potentially early event [<a href="#rid156">156-159</a>]. Furthermore, loss of CDKI1B protein expression in radical prostatectomy specimens has been shown to be an adverse prognostic factor in patients with clinically localized prostate cancer [<a href="#rid143">143,157,160-163</a>] and in those undergoing salvage prostatectomy after radiation therapy failure [<a href="#rid164">164</a>]. Because of this, loss of CDKI1B has been suggested as a component of molecular staging [<a href="#rid162">162,165</a>]. As with other putative tumor suppressor genes, preclinical studies with recombinant adenovirus expressing CDKI1B are underway [<a href="#rid166">166</a>].</p><p class="headingAnchor" id="H22"><span class="h3">Nkx3.1</span><span class="headingEndMark"> — </span><em>Nkx3.1</em> is an androgen-regulated prostate-specific homeobox gene on chromosome 8q that appears to be critical in the development of the normal prostate [<a href="#rid167">167,168</a>]. In some [<a href="#rid169">169-171</a>], but not all studies [<a href="#rid168">168,172</a>], decreased expression of <em>Nkx3.1</em> is associated with both PIN and invasive prostate cancer. Others have shown a correlation between abnormalities in <em>Nkx3.1</em> expression, and advanced-grade and castration-resistant disease [<a href="#rid171">171-173</a>].</p><p class="headingAnchor" id="H23"><span class="h3">KLF6</span><span class="headingEndMark"> — </span>Kruppel-like factor 6 (KLF6) is a zinc finger transcription factor. Its possible role as a tumor suppressor gene in prostate cancer was suggested in one series in which LOH for this allele was shown in 17 of 22 primary prostate tumors [<a href="#rid174">174</a>]. Further study of this gene and its role in prostate cancer is needed.</p><p class="headingAnchor" id="H24"><span class="h2">Metastasis suppressor genes</span><span class="headingEndMark"> — </span>Advanced prostate carcinoma is characterized by local invasion, spread to regional lymph nodes, and more distant osseous metastases. Much effort has been directed toward the identification and characterization of genes that are involved in metastatic behavior, both for the purpose of obtaining prognostic indicators for aggressive disease, and to understand why and how prostate cancer preferentially metastasizes to bone. (See  <a class="medical medical_review" href="/d/html/6948.html" rel="external">"Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis", section on 'Pathophysiology'</a>.)</p><p>The identification of several genes that appear to function as metastasis suppressor genes has provided important insight into factors regulating metastatic spread and growth. By definition, metastasis suppressor genes specifically prevent the formation of overt metastasis without affecting the formation or growth of primary tumors [<a href="#rid175">175,176</a>].</p><p>The technique of microcell-mediated chromosomal transfer (MMCT) has been the most commonly used method to identify putative metastasis suppressor genes in prostate cancer. It is based on the work of Ichikawa et al, who demonstrated that fusion of nonmetastatic and highly metastatic Dunning rat prostate carcinoma cells produced nonmetastatic hybrid cells that were unaffected in terms of tumorigenicity and in vitro growth rates [<a href="#rid177">177</a>]. Subsequent studies suggested that the loss of specific chromosomes was responsible for the metastatic phenotype. MMCT was then used to selectively introduce single, tagged human chromosomes into metastatic recipient cells, thereby permitting the localization of metastasis suppressor genes to specific human chromosomes. Two of the genes identified in the rat Dunning model (<em>KAI1 </em>and <em>CD44</em>) appear to suppress metastatic potential at an early stage of the metastatic cascade.</p><p class="headingAnchor" id="H25"><span class="h3">KAI-1/CD82</span><span class="headingEndMark"> — </span><em>KAI1 </em>was the first prostate cancer metastasis suppressor gene identified using MMCT; it maps to chromosome 11p11.2, and downregulation of this gene has been found in advanced prostate tumors and metastases [<a href="#rid178">178,179</a>]. The <em>KAI1</em> gene encodes a membrane glycoprotein that is widely expressed, but its precise biochemical function in metastasis suppression has not been clearly defined. In vitro studies suggest that it may play a role in integrin signaling, cell adhesion, and motility [<a href="#rid180">180-182</a>].</p><p class="headingAnchor" id="H27"><span class="h3">E-cadherin (16q22)</span><span class="headingEndMark"> — </span>E-cadherin (CDH1) is a Ca2+ dependent homotypic cell adhesion molecule that is implicated as a tumor/invasion suppressor in human carcinomas; it also functions as a binding partner for beta catenin, which is overexpressed in advanced prostate cancers. (See <a class="local">'Oncogenes'</a> above.)</p><p>Aberrant E-cadherin expression appears to be associated with high histologic grade and more aggressive tumor behavior [<a href="#rid183">183-186</a>], and deletions of chromosome 16q and/or loss of E-cadherin function are common in prostate cancer metastases [<a href="#rid187">187,188</a>]. Furthermore, using MMCT, 16q has been strongly associated with suppression of metastatic ability [<a href="#rid189">189</a>].</p><p>Additional evidence supporting the role of E-cadherin as a prognostic marker comes from the observation that decreased expression of E-cadherin and increased expression of N-cadherin are associated with adverse clinicopathologic features [<a href="#rid190">190</a>].</p><p class="headingAnchor" id="H29"><span class="h1">ACQUIRED CASTRATION RESISTANCE</span><span class="headingEndMark"> — </span>Although the majority of men have a favorable initial response to androgen ablation, the development of hormone resistance is inevitable and can be responsible for the lethality of advanced prostate cancer. Multiple mechanisms have been postulated to account for the acquisition of castration resistance. A detailed review of the specific molecular changes that are associated with castration resistance is beyond the scope of this discussion, although these changes are well reviewed elsewhere [<a href="#rid14">14,191</a>]. Here we will provide a brief overview of some of the mechanisms that are thought to underlie the development of castration resistance.</p><p>In view of the importance of androgens to the growth of prostate cancer, it is reasonable to ask if alterations in the androgen receptor (AR) could be responsible for androgen-independent growth [<a href="#rid192">192</a>]. The <em>AR</em> gene is overexpressed in approximately 20 to 30 percent of hormone-refractory prostate cancers [<a href="#rid193">193,194</a>], although more sensitive techniques, such as gene expression profiling, suggest that amplification is nearly universal when hormone-resistant human prostate cancer cell lines are compared with the hormone-sensitive tumors from which they were derived [<a href="#rid195">195</a>]. In theory, such alterations might possibly enhance the response of the cancer cell to low levels of endogenous androgens [<a href="#rid196">196,197</a>].</p><p>Activating mutations in the <em>AR</em> gene have also been reported [<a href="#rid198">198-200</a>]. Such mutations in the steroid binding domain may alter ligand specificity, allowing other nonandrogenic steroids, as well as antiandrogens, to bind and activate the mutant AR, even when the level of systemic androgen is fully suppressed. <em>AR</em> mutations have been most intensely studied in the context of the antiandrogen withdrawal response, in which acquired mutations in the <em>AR </em>are thought to result in a paradoxical stimulatory effect of antiandrogens on prostate tumor cells. Mutations in the hormone binding domain of the <em>AR</em> have been detected in a small fraction of bone marrow specimens of men with castration-resistant prostate cancer [<a href="#rid199">199-201</a>]. In functional studies, these mutant receptors were stimulated rather than inhibited by some, but not all, antiandrogens [<a href="#rid202">202</a>]. However, other data suggest that <em>AR </em>mutations are not responsible for the antiandrogen withdrawal response, and this remains a controversial area [<a href="#rid200">200</a>]. (See  <a class="medical medical_review" href="/d/html/6942.html" rel="external">"Alternative endocrine therapies for castration-resistant prostate cancer", section on 'Antiandrogen withdrawal'</a>.)</p><p>Other specific <em>AR</em> mutations and splice variants deleting the ligand binding domain provide an additional pathway for androgen escape in prostate cancer cells [<a href="#rid203">203,204</a>]. The predominant V7 AR splice variant has been strongly associated with castration resistance and overall poor patient survival [<a href="#rid203">203</a>]. (See  <a class="medical medical_review" href="/d/html/16351.html" rel="external">"Castration-resistant prostate cancer: Treatments targeting the androgen pathway", section on 'Resistance'</a>.)</p><p>Another mechanism for castration resistance growth involves molecular changes in several regulatory genes that may prevent the transcription or expression of death signaling genes after androgen ablation [<a href="#rid205">205,206</a>] or prevent the cancer cells from responding to these apoptotic influences through constitutive expression of genes that are located downstream in the apoptotic cascade (eg, upregulation of B cell leukemia/lymphoma [bcl-2], see above). Alternatively, resistance to androgen ablation might also involve "crosstalk" between the AR and other signaling pathways that are induced by peptide growth factors. In theory, androgen-independent AR activation could then be achieved via other pathways that are activated by specific peptide growth factor receptors [<a href="#rid207">207,208</a>].</p><p>Finally, molecular changes within the prostate cancer cells may result in the ability to synthesize and secrete specific ligands and their receptors, essentially creating an autocrine survival pathway that is independent of androgen signaling pathways [<a href="#rid209">209</a>]. One such example is the secretion of neurotrophin ligands and their trk receptors by hormone-resistant prostate cancer cells [<a href="#rid210">210</a>]. Small molecule inhibitors of these tyrosine kinase receptors can induce apoptosis in hormone-resistant prostate cancer cells [<a href="#rid211">211,212</a>], and these trk inhibitors are currently in clinical trials.</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY</span><span class="headingEndMark"> — </span>Prostate cancer continues to be a major health problem despite significant advances in prevention and early detection. The mechanistic characterization of genes shown to play a functional role in the development and progression of prostate cancer is beginning to provide important insights into the nature and behavior of the disease. The goal of these studies is to identify additional targets for staging and treatment.</p><p class="headingAnchor" id="H2071921501"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>We are saddened by the death of Nicholas Vogelzang, MD, who passed away in September 2022. UpToDate gratefully acknowledges Dr. Vogelzang's role as Section Editor on this topic, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28:251.</a></li><li><a class="nounderline abstract_t">Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990; 50:3748.</a></li><li><a class="nounderline abstract_t">Gao J, Isaacs JT. Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells. Cancer Res 1998; 58:3299.</a></li><li><a class="nounderline abstract_t">Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26:263.</a></li><li><a class="nounderline abstract_t">Miller DC, Hafez KS, Stewart A, et al. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer 2003; 98:1169.</a></li><li><a class="nounderline abstract_t">Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol 2003; 170:2444.</a></li><li><a class="nounderline abstract_t">Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349:366.</a></li><li><a class="nounderline abstract_t">Moul JW, Merseburger AS, Srivastava S. Molecular markers in prostate cancer: the role in preoperative staging. Clin Prostate Cancer 2002; 1:42.</a></li><li><a class="nounderline abstract_t">Alers JC, Rochat J, Krijtenburg PJ, et al. Identification of genetic markers for prostatic cancer progression. Lab Invest 2000; 80:931.</a></li><li><a class="nounderline abstract_t">Wolter H, Trijic D, Gottfried HW, Mattfeldt T. Chromosomal changes in incidental prostatic carcinomas detected by comparative genomic hybridization. Eur Urol 2002; 41:328.</a></li><li><a class="nounderline abstract_t">Qian J, Jenkins RB, Bostwick DG. Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Eur Urol 1999; 35:479.</a></li><li><a class="nounderline abstract_t">Karan D, Schmied BM, Dave BJ, et al. Decreased androgen-responsive growth of human prostate cancer is associated with increased genetic alterations. Clin Cancer Res 2001; 7:3472.</a></li><li><a class="nounderline abstract_t">Ozen M, Pathak S. Genetic alterations in human prostate cancer: a review of current literature. Anticancer Res 2000; 20:1905.</a></li><li><a class="nounderline abstract_t">Elo JP, Visakorpi T. Molecular genetics of prostate cancer. Ann Med 2001; 33:130.</a></li><li><a class="nounderline abstract_t">Sato K, Qian J, Slezak JM, et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999; 91:1574.</a></li><li><a class="nounderline abstract_t">Buttyan R, Sawczuk IS, Benson MC, et al. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 1987; 11:327.</a></li><li><a class="nounderline abstract_t">Qian J, Hirasawa K, Bostwick DG, et al. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol 2002; 15:35.</a></li><li><a class="nounderline abstract_t">Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997; 57:524.</a></li><li><a class="nounderline abstract_t">Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 59:803.</a></li><li><a class="nounderline abstract_t">Karan D, Kelly DL, Rizzino A, et al. Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 2002; 23:967.</a></li><li><a class="nounderline abstract_t">Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998; 153:141.</a></li><li><a class="nounderline abstract_t">Magi-Galluzzi C, Mishra R, Fiorentino M, et al. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest 1997; 76:37.</a></li><li><a class="nounderline abstract_t">Magi-Galluzzi C, Montironi R, Cangi MG, et al. Mitogen-activated protein kinases and apoptosis in PIN. Virchows Arch 1998; 432:407.</a></li><li><a class="nounderline abstract_t">Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis 2003; 8:29.</a></li><li><a class="nounderline abstract_t">Apakama I, Robinson MC, Walter NM, et al. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996; 74:1258.</a></li><li><a class="nounderline abstract_t">Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993; 143:390.</a></li><li><a class="nounderline abstract_t">Furuya Y, Krajewski S, Epstein JI, et al. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996; 2:389.</a></li><li><a class="nounderline abstract_t">McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 1997; 157:569.</a></li><li><a class="nounderline abstract_t">Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85:1657.</a></li><li><a class="nounderline abstract_t">Stattin P, Damber JE, Karlberg L, et al. Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol Res 1996; 24:257.</a></li><li><a class="nounderline abstract_t">Baltaci S, Orhan D, Ozer G, et al. Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia. BJU Int 2000; 85:155.</a></li><li><a class="nounderline abstract_t">Bonkhoff H, Fixemer T, Remberger K. Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 1998; 34:251.</a></li><li><a class="nounderline abstract_t">Gleave ME, Zellweger T, Chi K, et al. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest New Drugs 2002; 20:145.</a></li><li><a class="nounderline abstract_t">Vilenchik M, Raffo AJ, Benimetskaya L, et al. Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents. Cancer Res 2002; 62:2175.</a></li><li><a class="nounderline abstract_t">Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000; 92:34.</a></li><li><a class="nounderline abstract_t">Bauer JJ, Sesterhenn IA, Mostofi FK, et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996; 156:1511.</a></li><li><a class="nounderline abstract_t">Stackhouse GB, Sesterhenn IA, Bauer JJ, et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999; 162:2040.</a></li><li><a class="nounderline abstract_t">Brewster SF, Oxley JD, Trivella M, et al. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 1999; 161:1238.</a></li><li><a class="nounderline abstract_t">Concato J, Jain D, Uchio E, et al. Molecular markers and death from prostate cancer. Ann Intern Med 2009; 150:595.</a></li><li><a class="nounderline abstract_t">Hahn WC. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 2003; 21:2034.</a></li><li><a class="nounderline abstract_t">Kageyama Y, Kamata S, Yonese J, Oshima H. Telomere length and telomerase activity in bladder and prostate cancer cell lines. Int J Urol 1997; 4:407.</a></li><li><a class="nounderline abstract_t">Koeneman KS, Pan CX, Jin JK, et al. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). J Urol 1998; 160:1533.</a></li><li><a class="nounderline abstract_t">Ozen M, Imam SA, Datar RH, et al. Telomeric DNA: marker for human prostate cancer development? Prostate 1998; 36:264.</a></li><li><a class="nounderline abstract_t">Paradis V, Dargère D, Laurendeau I, et al. Expression of the RNA component of human telomerase (hTR) in prostate cancer, prostatic intraepithelial neoplasia, and normal prostate tissue. J Pathol 1999; 189:213.</a></li><li><a class="nounderline abstract_t">Zhang W, Kapusta LR, Slingerland JM, Klotz LH. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res 1998; 58:619.</a></li><li><a class="nounderline abstract_t">Iczkowski KA, Pantazis CG, McGregor DH, et al. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma. Cancer 2002; 95:2487.</a></li><li><a class="nounderline abstract_t">Wang Z, Ramin SA, Tsai C, et al. Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens. Urol Oncol 2001; 6:57.</a></li><li><a class="nounderline abstract_t">Bearss DJ, Hurley LH, Von Hoff DD. Telomere maintenance mechanisms as a target for drug development. Oncogene 2000; 19:6632.</a></li><li><a class="nounderline abstract_t">Wang J, Krill D, Torbenson M, et al. Expression of cadherins and catenins in paired tumor and non-neoplastic primary prostate cultures and corresponding prostatectomy specimens. Urol Res 2000; 28:308.</a></li><li><a class="nounderline abstract_t">Kallakury BV, Sheehan CE, Ross JS. Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum Pathol 2001; 32:849.</a></li><li><a class="nounderline abstract_t">Chesire DR, Ewing CM, Sauvageot J, et al. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000; 45:323.</a></li><li><a class="nounderline abstract_t">Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998; 58:2520.</a></li><li><a class="nounderline abstract_t">Truica CI, Byers S, Gelmann EP. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000; 60:4709.</a></li><li><a class="nounderline abstract_t">Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002; 21:2679.</a></li><li><a class="nounderline abstract_t">Gumerlock PH, Poonamallee UR, Meyers FJ, deVere White RW. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res 1991; 51:1632.</a></li><li><a class="nounderline abstract_t">Carter BS, Epstein JI, Isaacs WB. ras gene mutations in human prostate cancer. Cancer Res 1990; 50:6830.</a></li><li><a class="nounderline abstract_t">Shiraishi T, Muneyuki T, Fukutome K, et al. Mutations of ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations. Anticancer Res 1998; 18:2789.</a></li><li><a class="nounderline abstract_t">Konishi N, Hiasa Y, Tsuzuki T, et al. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate 1997; 30:53.</a></li><li><a class="nounderline abstract_t">Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002; 21:6835.</a></li><li><a class="nounderline abstract_t">Kuzmin I, Gillespie JW, Protopopov A, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002; 62:3498.</a></li><li><a class="nounderline abstract_t">Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97:103.</a></li><li><a class="nounderline abstract_t">Duggan D, Zheng SL, Knowlton M, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99:1836.</a></li><li><a class="nounderline abstract_t">Osman I, Scher HI, Drobnjak M, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001; 7:2643.</a></li><li><a class="nounderline abstract_t">Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92:1918.</a></li><li><a class="nounderline abstract_t">Kallakury BV, Sheehan CE, Ambros RA, et al. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol 1998; 16:1302.</a></li><li><a class="nounderline abstract_t">Ross JS, Sheehan CE, Hayner-Buchan AM, et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997; 79:2162.</a></li><li><a class="nounderline abstract_t">Mark HF, Feldman D, Das S, et al. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp Mol Pathol 1999; 66:170.</a></li><li><a class="nounderline abstract_t">Schlomm T, Kirstein P, Iwers L, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007; 13:6579.</a></li><li><a class="nounderline abstract_t">Migita T, Ruiz S, Fornari A, et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009; 101:519.</a></li><li><a class="nounderline abstract_t">Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012; 366:141.</a></li><li><a class="nounderline abstract_t">Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644.</a></li><li><a class="nounderline abstract_t">Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008; 68:73.</a></li><li><a class="nounderline abstract_t">Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20:538.</a></li><li><a class="nounderline abstract_t">Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66:8337.</a></li><li><a class="nounderline abstract_t">Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009; 15:4706.</a></li><li><a class="nounderline abstract_t">Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007; 97:1690.</a></li><li><a class="nounderline abstract_t">Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100:387.</a></li><li><a class="nounderline abstract_t">Latini JM, Rieger-Christ KM, Wang DS, et al. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions. J Urol 2001; 166:1931.</a></li><li><a class="nounderline abstract_t">Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 1998; 95:5246.</a></li><li><a class="nounderline abstract_t">Gray IC, Phillips SM, Lee SJ, et al. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 1995; 55:4800.</a></li><li><a class="nounderline abstract_t">Rubin MA, Gerstein A, Reid K, et al. 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. Hum Pathol 2000; 31:504.</a></li><li><a class="nounderline abstract_t">Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57:4997.</a></li><li><a class="nounderline abstract_t">Dong JT, Sipe TW, Hyytinen ER, et al. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 1998; 17:1979.</a></li><li><a class="nounderline abstract_t">Feilotter HE, Nagai MA, Boag AH, et al. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998; 16:1743.</a></li><li><a class="nounderline abstract_t">Pesche S, Latil A, Muzeau F, et al. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 1998; 16:2879.</a></li><li><a class="nounderline abstract_t">Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998; 58:204.</a></li><li><a class="nounderline abstract_t">Wang SI, Parsons R, Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998; 4:811.</a></li><li><a class="nounderline abstract_t">Vlietstra RJ, van Alewijk DC, Hermans KG, et al. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998; 58:2720.</a></li><li><a class="nounderline abstract_t">Huang H, Cheville JC, Pan Y, et al. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 2001; 276:38830.</a></li><li><a class="nounderline abstract_t">Davies MA, Kim SJ, Parikh NU, et al. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 2002; 8:1904.</a></li><li><a class="nounderline abstract_t">Schreiber-Agus N, Meng Y, Hoang T, et al. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 1998; 393:483.</a></li><li><a class="nounderline abstract_t">Eagle LR, Yin X, Brothman AR, et al. Mutation of the MXI1 gene in prostate cancer. Nat Genet 1995; 9:249.</a></li><li><a class="nounderline abstract_t">Prochownik EV, Eagle Grove L, Deubler D, et al. Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Genes Chromosomes Cancer 1998; 22:295.</a></li><li><a class="nounderline abstract_t">Kawamata N, Park D, Wilczynski S, et al. Point mutations of the Mxil gene are rare in prostate cancers. Prostate 1996; 29:191.</a></li><li><a class="nounderline abstract_t">Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 1994; 91:11733.</a></li><li><a class="nounderline abstract_t">Mannervik B, Alin P, Guthenberg C, et al. Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc Natl Acad Sci U S A 1985; 82:7202.</a></li><li><a class="nounderline abstract_t">Lee WH, Isaacs WB, Bova GS, Nelson WG. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev 1997; 6:443.</a></li><li><a class="nounderline abstract_t">Brooks JD, Weinstein M, Lin X, et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 1998; 7:531.</a></li><li><a class="nounderline abstract_t">Mirchandani D, Zheng J, Miller GJ, et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995; 147:92.</a></li><li><a class="nounderline abstract_t">Meyers FJ, Gumerlock PH, Chi SG, et al. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 1998; 83:2534.</a></li><li><a class="nounderline abstract_t">Navone NM, Labate ME, Troncoso P, et al. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 1999; 161:304.</a></li><li><a class="nounderline abstract_t">Voeller HJ, Sugars LY, Pretlow T, Gelmann EP. p53 oncogene mutations in human prostate cancer specimens. J Urol 1994; 151:492.</a></li><li><a class="nounderline abstract_t">Al-Maghrabi J, Vorobyova L, Chapman W, et al. p53 Alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens. Mod Pathol 2001; 14:1252.</a></li><li><a class="nounderline abstract_t">Downing SR, Jackson P, Russell PJ. Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. a review of the evidence. Urol Oncol 2001; 6:103.</a></li><li><a class="nounderline abstract_t">Tamboli P, Amin MB, Xu HJ, Linden MD. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate. Mod Pathol 1998; 11:247.</a></li><li><a class="nounderline abstract_t">Myers RB, Oelschlager D, Srivastava S, Grizzle WE. Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 1994; 25:243.</a></li><li><a class="nounderline abstract_t">Bookstein R, MacGrogan D, Hilsenbeck SG, et al. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993; 53:3369.</a></li><li><a class="nounderline abstract_t">Visakorpi T, Kallioniemi OP, Heikkinen A, et al. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992; 84:883.</a></li><li><a class="nounderline abstract_t">Fan K, Dao DD, Schutz M, Fink LM. Loss of heterozygosity and overexpression of p53 gene in human primary prostatic adenocarcinoma. Diagn Mol Pathol 1994; 3:265.</a></li><li><a class="nounderline abstract_t">Macera MJ, Godec CJ, Sharma N, Verma RS. Loss of heterozygosity of the TP53 tumor suppressor gene and detection of point mutations by the non-isotopic RNAse cleavage assay in prostate cancer. Cancer Genet Cytogenet 1999; 108:42.</a></li><li><a class="nounderline abstract_t">Effert PJ, McCoy RH, Walther PJ, Liu ET. p53 gene alterations in human prostate carcinoma. J Urol 1993; 150:257.</a></li><li><a class="nounderline abstract_t">Aprikian AG, Sarkis AS, Fair WR, et al. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994; 151:1276.</a></li><li><a class="nounderline abstract_t">Kallakury BV, Figge J, Ross JS, et al. Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma. Hum Pathol 1994; 25:92.</a></li><li><a class="nounderline abstract_t">Burchardt M, Burchardt T, Shabsigh A, et al. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells. Prostate 2001; 48:225.</a></li><li><a class="nounderline abstract_t">Quinn DI, Henshall SM, Head DR, et al. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 2000; 60:1585.</a></li><li><a class="nounderline abstract_t">Stapleton AM, Timme TL, Gousse AE, et al. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 1997; 3:1389.</a></li><li><a class="nounderline abstract_t">D'Amico AV, Halabi S, Vollmer R, et al. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology 2008; 71:933.</a></li><li><a class="nounderline abstract_t">Khor LY, Bae K, Paulus R, et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol 2009; 27:3177.</a></li><li><a class="nounderline abstract_t">Ruijter E, van de Kaa C, Aalders T, et al. Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. BIOMED-II Markers for Prostate Cancer Study Group. Mod Pathol 1998; 11:276.</a></li><li><a class="nounderline abstract_t">Grignon DJ, Caplan R, Sarkar FH, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997; 89:158.</a></li><li><a class="nounderline abstract_t">Eastham JA, Grafton W, Martin CM, Williams BJ. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J Urol 2000; 164:814.</a></li><li><a class="nounderline abstract_t">Seki M, Iwakawa J, Cheng H, Cheng PW. p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. Hum Gene Ther 2002; 13:761.</a></li><li><a class="nounderline abstract_t">Glynne-Jones E, Harper ME, Goddard L, et al. Transforming growth factor beta 1 expression in benign and malignant prostatic tumors. Prostate 1994; 25:210.</a></li><li><a class="nounderline abstract_t">Kim IY, Ahn HJ, Zelner DJ, et al. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996; 2:1255.</a></li><li><a class="nounderline abstract_t">Wikström P, Stattin P, Franck-Lissbrant I, et al. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998; 37:19.</a></li><li><a class="nounderline abstract_t">Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000; 42:150.</a></li><li><a class="nounderline abstract_t">Kim IY, Ahn HJ, Lang S, et al. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 1998; 4:1625.</a></li><li><a class="nounderline abstract_t">Shariat SF, Shalev M, Menesses-Diaz A, et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001; 19:2856.</a></li><li><a class="nounderline abstract_t">Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003; 21:3573.</a></li><li><a class="nounderline abstract_t">Hyytinen ER, Frierson HF Jr, Boyd JC, et al. Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer 1999; 25:108.</a></li><li><a class="nounderline abstract_t">Fiedler U, Ehlers W, Meye A, et al. LOH analyses in the region of the putative tumour suppressor gene C13 on chromosome 13q13. Anticancer Res 2001; 21:2341.</a></li><li><a class="nounderline abstract_t">Jarrard DF, Sarkar S, Shi Y, et al. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res 1999; 59:2957.</a></li><li><a class="nounderline abstract_t">Bookstein R, Rio P, Madreperla SA, et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci U S A 1990; 87:7762.</a></li><li><a class="nounderline abstract_t">Li C, Larsson C, Futreal A, et al. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 1998; 16:481.</a></li><li><a class="nounderline abstract_t">Tricoli JV, Gumerlock PH, Yao JL, et al. Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosomes Cancer 1996; 15:108.</a></li><li><a class="nounderline abstract_t">Chi SG, deVere White RW, Muenzer JT, Gumerlock PH. Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas. Clin Cancer Res 1997; 3:1889.</a></li><li><a class="nounderline abstract_t">Chakravarti A, DeSilvio M, Zhang M, et al. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. J Clin Oncol 2007; 25:3082.</a></li><li><a class="nounderline abstract_t">Gu K, Mes-Masson AM, Gauthier J, Saad F. Analysis of the p16 tumor suppressor gene in early-stage prostate cancer. Mol Carcinog 1998; 21:164.</a></li><li><a class="nounderline abstract_t">Mangold KA, Takahashi H, Brandigi C, et al. p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan. J Urol 1997; 157:1117.</a></li><li><a class="nounderline abstract_t">Heidenreich B, Heidenreich A, Sesterhenn A, et al. Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer. Eur Urol 2000; 38:475.</a></li><li><a class="nounderline abstract_t">Jarrard DF, Modder J, Fadden P, et al. Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett 2002; 185:191.</a></li><li><a class="nounderline abstract_t">Phillips SM, Barton CM, Lee SJ, et al. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994; 70:1252.</a></li><li><a class="nounderline abstract_t">Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998; 159:941.</a></li><li><a class="nounderline abstract_t">Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995; 11:210.</a></li><li><a class="nounderline abstract_t">Chen W, Weghorst CM, Sabourin CL, et al. Absence of p16/MTS1 gene mutations in human prostate cancer. Carcinogenesis 1996; 17:2603.</a></li><li><a class="nounderline abstract_t">Kaltz-Wittmer C, Klenk U, Glaessgen A, et al. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 2000; 80:1455.</a></li><li><a class="nounderline abstract_t">Sarkar FH, Sakr W, Li YW, et al. Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas. Prostate 1992; 21:145.</a></li><li><a class="nounderline abstract_t">Bookstein R, Shew JY, Chen PL, et al. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 1990; 247:712.</a></li><li><a class="nounderline abstract_t">Steiner MS, Zhang Y, Farooq F, et al. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Ther 2000; 7:360.</a></li><li><a class="nounderline abstract_t">Fizazi K, Martinez LA, Sikes CR, et al. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 2002; 8:775.</a></li><li><a class="nounderline abstract_t">Sarkar FH, Li Y, Sakr WA, et al. Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa). Prostate 1999; 40:256.</a></li><li><a class="nounderline abstract_t">Osman I, Drobnjak M, Fazzari M, et al. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 1999; 5:2082.</a></li><li><a class="nounderline abstract_t">Baretton GB, Klenk U, Diebold J, et al. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 1999; 80:546.</a></li><li><a class="nounderline abstract_t">Martinez LA, Yang J, Vazquez ES, et al. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 2002; 23:1289.</a></li><li><a class="nounderline abstract_t">Kibel AS, Schutte M, Kern SE, et al. Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res 1998; 58:5652.</a></li><li><a class="nounderline abstract_t">Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997; 3:2269.</a></li><li><a class="nounderline abstract_t">Cordon-Cardo C, Koff A, Drobnjak M, et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998; 90:1284.</a></li><li><a class="nounderline abstract_t">Erdamar S, Yang G, Harper JW, et al. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol 1999; 12:751.</a></li><li><a class="nounderline abstract_t">Fernández PL, Arce Y, Farré X, et al. Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J Pathol 1999; 187:563.</a></li><li><a class="nounderline abstract_t">Tsihlias J, Kapusta LR, DeBoer G, et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998; 58:542.</a></li><li><a class="nounderline abstract_t">Cote RJ, Shi Y, Groshen S, et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998; 90:916.</a></li><li><a class="nounderline abstract_t">Vis AN, van Rhijn BW, Noordzij MA, et al. Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol 2002; 197:148.</a></li><li><a class="nounderline abstract_t">Thomas GV, Schrage MI, Rosenfelt L, et al. Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage. J Urol 2000; 164:1987.</a></li><li><a class="nounderline abstract_t">Cheng L, Lloyd RV, Weaver AL, et al. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 2000; 6:1896.</a></li><li><a class="nounderline abstract_t">Moul JW, Kane CJ, Malkowicz SB. The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. Urol Clin North Am 2001; 28:459.</a></li><li><a class="nounderline abstract_t">Katner AL, Hoang QB, Gootam P, et al. Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1). Prostate 2002; 53:77.</a></li><li><a class="nounderline abstract_t">Schneider A, Brand T, Zweigerdt R, Arnold H. Targeted disruption of the Nkx3.1 gene in mice results in morphogenetic defects of minor salivary glands: parallels to glandular duct morphogenesis in prostate. Mech Dev 2000; 95:163.</a></li><li><a class="nounderline abstract_t">Ornstein DK, Cinquanta M, Weiler S, et al. Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. J Urol 2001; 165:1329.</a></li><li><a class="nounderline abstract_t">Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 2002; 62:2999.</a></li><li><a class="nounderline abstract_t">Abdulkadir SA, Magee JA, Peters TJ, et al. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 2002; 22:1495.</a></li><li><a class="nounderline abstract_t">Bowen C, Bubendorf L, Voeller HJ, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000; 60:6111.</a></li><li><a class="nounderline abstract_t">Xu LL, Srikantan V, Sesterhenn IA, et al. Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J Urol 2000; 163:972.</a></li><li><a class="nounderline abstract_t">He WW, Sciavolino PJ, Wing J, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997; 43:69.</a></li><li><a class="nounderline abstract_t">Narla G, Heath KE, Reeves HL, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001; 294:2563.</a></li><li><a class="nounderline abstract_t">Jaeger EB, Samant RS, Rinker-Schaeffer CW. Metastasis suppression in prostate cancer. Cancer Metastasis Rev 2001; 20:279.</a></li><li><a class="nounderline abstract_t">Kauffman EC, Robinson VL, Stadler WM, et al. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol 2003; 169:1122.</a></li><li><a class="nounderline abstract_t">Ichikawa T, Ichikawa Y, Isaacs JT. Genetic factors and suppression of metastatic ability of prostatic cancer. Cancer Res 1991; 51:3788.</a></li><li><a class="nounderline abstract_t">Dong JT, Lamb PW, Rinker-Schaeffer CW, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268:884.</a></li><li><a class="nounderline abstract_t">Bouras T, Frauman AG. Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade. J Pathol 1999; 188:382.</a></li><li><a class="nounderline abstract_t">Kawana Y, Komiya A, Ueda T, et al. Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate 1997; 32:205.</a></li><li><a class="nounderline abstract_t">Dong JT, Suzuki H, Pin SS, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996; 56:4387.</a></li><li><a class="nounderline abstract_t">Ueda T, Ichikawa T, Tamaru J, et al. Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J Pathol 1996; 149:1435.</a></li><li><a class="nounderline abstract_t">Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54:3929.</a></li><li><a class="nounderline abstract_t">Otto T, Rembrink K, Goepel M, et al. E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma. Urol Res 1993; 21:359.</a></li><li><a class="nounderline abstract_t">Richmond PJ, Karayiannakis AJ, Nagafuchi A, et al. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 1997; 57:3189.</a></li><li><a class="nounderline abstract_t">Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995; 55:5195.</a></li><li><a class="nounderline abstract_t">Pan Y, Matsuyama H, Wang N, et al. Chromosome 16q24 deletion and decreased E-cadherin expression: possible association with metastatic potential in prostate cancer. Prostate 1998; 36:31.</a></li><li><a class="nounderline abstract_t">Latil A, Cussenot O, Fournier G, et al. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. Cancer Res 1997; 57:1058.</a></li><li><a class="nounderline abstract_t">Mashimo T, Watabe M, Cuthbert AP, et al. Human chromosome 16 suppresses metastasis but not tumorigenesis in rat prostatic tumor cells. Cancer Res 1998; 58:4572.</a></li><li><a class="nounderline abstract_t">Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007; 13:7003.</a></li><li><a class="nounderline abstract_t">Cude KJ, Dixon SC, Guo Y, et al. The androgen receptor: genetic considerations in the development and treatment of prostate cancer. J Mol Med (Berl) 1999; 77:419.</a></li><li><a class="nounderline abstract_t">Culig Z, Klocker H, Bartsch G, et al. Androgen receptors in prostate cancer. J Urol 2003; 170:1363.</a></li><li><a class="nounderline abstract_t">Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57:314.</a></li><li><a class="nounderline abstract_t">Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89:552.</a></li><li><a class="nounderline abstract_t">Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10:33.</a></li><li><a class="nounderline abstract_t">Hyytinen ER, Haapala K, Thompson J, et al. Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest 2002; 82:1591.</a></li><li><a class="nounderline abstract_t">Mohler JL, Gregory CW, Ford OH 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10:440.</a></li><li><a class="nounderline abstract_t">Wallén MJ, Linja M, Kaartinen K, et al. Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 1999; 189:559.</a></li><li><a class="nounderline abstract_t">Suzuki H, Akakura K, Komiya A, et al. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996; 29:153.</a></li><li><a class="nounderline abstract_t">Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21:2673.</a></li><li><a class="nounderline abstract_t">Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332:1393.</a></li><li><a class="nounderline abstract_t">Fenton MA, Shuster TD, Fertig AM, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997; 3:1383.</a></li><li><a class="nounderline abstract_t">Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371:1028.</a></li><li><a class="nounderline abstract_t">Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68:5469.</a></li><li><a class="nounderline abstract_t">Chang GT, Steenbeek M, Schippers E, et al. Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells. J Natl Cancer Inst 2000; 92:1414.</a></li><li><a class="nounderline abstract_t">July LV, Akbari M, Zellweger T, et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50:179.</a></li><li><a class="nounderline abstract_t">Abreu-Martin MT, Chari A, Palladino AA, et al. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 1999; 19:5143.</a></li><li><a class="nounderline abstract_t">Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5:280.</a></li><li><a class="nounderline abstract_t">Isaacs JT. Apoptosis: translating theory to therapy for prostate cancer. J Natl Cancer Inst 2000; 92:1367.</a></li><li><a class="nounderline abstract_t">Weeraratna AT, Dalrymple SL, Lamb JC, et al. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res 2001; 7:2237.</a></li><li><a class="nounderline abstract_t">Dionne CA, Camoratto AM, Jani JP, et al. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 1998; 4:1887.</a></li><li><a class="nounderline abstract_t">George DJ, Dionne CA, Jani J, et al. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 1999; 59:2395.</a></li></ol></div><div id="topicVersionRevision">Topic 6926 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8602401" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2340521" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9699659" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10361549" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The biology of hormone refractory prostate cancer. Why does it develop?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12973840" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14634448" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Molecular pathways to prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12878745" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15046712" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Molecular markers in prostate cancer: the role in preoperative staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10879743" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Identification of genetic markers for prostatic cancer progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12180237" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chromosomal changes in incidental prostatic carcinomas detected by comparative genomic hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10325509" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11705865" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Decreased androgen-responsive growth of human prostate cancer is associated with increased genetic alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928125" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genetic alterations in human prostate cancer: a review of current literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11327116" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Molecular genetics of prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10491435" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2446300" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11796839" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9012485" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10029066" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12082018" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9665474" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Genetic alterations in hormone-refractory recurrent prostate carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9010448" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9645439" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mitogen-activated protein kinases and apoptosis in PIN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12510149" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : BCL-2 in prostate cancer: a minireview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8883414" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7688182" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9816182" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Expression of bcl-2 and the progression of human and rodent prostatic cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996359" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7692074" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8931289" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619965" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9496899" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12099575" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11929841" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620631" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8808919" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10569564" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10081877" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414838" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Molecular markers and death from prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743159" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Role of telomeres and telomerase in the pathogenesis of human cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9256332" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Telomere length and telomerase activity in bladder and prostate cancer cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9751408" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9719027" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Telomeric DNA: marker for human prostate cancer development?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10547577" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Expression of the RNA component of human telomerase (hTR) in prostate cancer, prostatic intraepithelial neoplasia, and normal prostate tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9485010" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12467061" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11166622" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11426649" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Telomere maintenance mechanisms as a target for drug development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11127708" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Expression of cadherins and catenins in paired tumor and non-neoplastic primary prostate cultures and corresponding prostatectomy specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11521230" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11102958" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Detection and analysis of beta-catenin mutations in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9635571" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Beta-catenin mutations in human prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10987273" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11965541" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1998954" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Activated ras alleles in human carcinoma of the prostate are rare.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2208148" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : ras gene mutations in human prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9713462" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mutations of ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9018336" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of ras activation in prostate carcinoma in Japanese and American men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12360410" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Frequent hypermethylation of the RASSF1A gene in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12067994" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15657340" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Epigenetic changes in prostate cancer: implication for diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18073375" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11555574" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11106683" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Her-2-neu expression and progression toward androgen independence in human prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552030" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9179063" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10409446" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18006757" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19318631" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22236224" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Germline mutations in HOXB13 and prostate-cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254181" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172298" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17334343" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16951139" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19584163" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17971772" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10693755" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The multiple roles of PTEN in tumor suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11586263" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9560261" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7585509" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Loss of the chromosomal region 10q23-25 in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10821499" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371490" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9788441" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9582022" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Analysis of PTEN and the 10q23 region in primary prostate carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9671408" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : PTEN/MMAC1/TEP1 involvement in primary prostate cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9443392" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9533551" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661880" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11495901" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12060635" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9624006" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7773287" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Mutation of the MXI1 gene in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669667" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Commonly occurring loss and mutation of the MXI1 gene in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8827088" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Point mutations of the Mxil gene are rare in prostate cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7972132" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3864155" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9184779" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9641498" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7604888" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9874460" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10037428" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7904314" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : p53 oncogene mutations in human prostate cancer specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11743048" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : p53 Alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11344000" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. a review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521470" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7971515" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8324747" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : p53 is mutated in a subset of advanced-stage prostate cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1350643" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7866637" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Loss of heterozygosity and overexpression of p53 gene in human primary prostatic adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9973923" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Loss of heterozygosity of the TP53 tumor suppressor gene and detection of point mutations by the non-isotopic RNAse cleavage assay in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8510267" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : p53 gene alterations in human prostate carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8158773" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7508886" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11536301" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10749127" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815823" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18291508" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470936" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521475" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. BIOMED-II Markers for Prostate Cancer Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8998185" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10953161" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11936974" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7521962" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Transforming growth factor beta 1 expression in benign and malignant prostatic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9816295" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9721065" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10617873" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Dysregulated expression of growth factors and their receptors in the development of prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9676836" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11387358" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12913106" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10337994" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11724291" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : LOH analyses in the region of the putative tumour suppressor gene C13 on chromosome 13q13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10383161" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2217208" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9484837" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Identification of two distinct deleted regions on chromosome 13 in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8834174" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Alterations of the retinoblastoma gene in human prostate adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815578" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634487" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9537647" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Analysis of the p16 tumor suppressor gene in early-stage prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9072554" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11025389" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12169393" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7526887" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9474188" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Low p27 expression predicts poor disease-free survival in patients with prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7550353" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006095" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Absence of p16/MTS1 gene mutations in human prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11005213" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1329054" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2300823" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10766342" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11895908" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10420154" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10473090" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10408865" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12151346" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9865716" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Identification of 12p as a region of frequent deletion in advanced prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815624" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731735" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10463475" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10398122" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9458103" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9637141" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015737" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11061897" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10815913" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11590806" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12210483" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10906459" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Targeted disruption of the Nkx3.1 gene in mice results in morphogenetic defects of minor salivary glands: parallels to glandular duct morphogenesis in prostate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11257711" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12036903" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11839815" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11085535" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10688034" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9226374" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11752579" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : KLF6, a candidate tumor suppressor gene mutated in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12085966" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Metastasis suppression in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576866" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2065333" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Genetic factors and suppression of metastatic ability of prostatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7754374" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440748" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9254900" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8813131" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8909232" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7518346" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7506464" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9242448" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7585573" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9650913" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Chromosome 16q24 deletion and decreased E-cadherin expression: possible association with metastatic potential in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9067271" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9788603" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Human chromosome 16 suppresses metastasis but not tumorigenesis in rat prostatic tumor cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056176" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10426191" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : The androgen receptor: genetic considerations in the development and treatment of prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14501770" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Androgen receptors in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9000575" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12888829" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14702632" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Molecular determinants of resistance to antiandrogen therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12429819" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760063" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : The androgen axis in recurrent prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10629558" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Androgen receptor gene mutations in hormone-refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8827083" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860943" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7723794" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815822" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25184630" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18593950" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10974077" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11813210" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10373563" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086382" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10974062" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Apoptosis: translating theory to therapy for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11489797" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9717816" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10344749" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
